INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 48m ago
HOUSE PTR7m ago
SEC 13F7m ago
ROBINHOOD CHAIN7m ago
Corporate insider
DB

Derakhshan Behrad

Chief Business OfficerCIK 0001853109

EDGAR filingsOpen in network
Disclosed transactions10
Buys / sells0 / 4
Max Insider Score33
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
21
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Option exercise
M—
5,781 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Edgewise Therapeutics, Inc.Chief Business Officer · Aug 14, 2026
17
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Option exercise
M
—
5,781 sh
Aug 12, 2026
Aug 14, 2026
traded Aug 12, 2026
+2d
SEC FORM 4

Evidence

17
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Option exercise
M—
7,500 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

33
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Open-market sale
SELL$95K
2,171 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

26
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Open-market sale
SELL$14K
304 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

26
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Open-market sale
SELL$6,666
150 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

33
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Open-market sale
SELL$108K
2,475 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

21
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Option exercise
M—
7,500 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

9
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Grant or award
A—
50.0K sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

9
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Grant or award
A—
100.0K sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence